CELC Celcuity Inc.

Nasdaq celcuity.com


$ 71.64 $ 0.21 (0.3 %)    

Tuesday, 21-Oct-2025 11:50:19 EDT
QQQ $ 612.11 $ 0.58 (0.09 %)
DIA $ 470.33 $ 3.21 (0.69 %)
SPY $ 672.41 $ 0.91 (0.14 %)
TLT $ 92.01 $ 0.02 (0.02 %)
GLD $ 380.88 $ -5.76 (-1.49 %)
$ 70.58
$ 71.35
$ 71.23 x 160
$ 71.75 x 56
$ 70.00 - $ 74.10
$ 7.58 - $ 83.00
7,339,933
na
2.99B
$ 0.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 02-16-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-13-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
31 03-15-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-celcuity-maintains-70-price-target

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

 reported-saturday-celcuity-presented-phase-1-data-at-esmo-2025-showing-gedatolisib-plus-darolutamide-delivers-91-month-median-rpfs-in-mcrpc-with-favorable-safety-profile-and-no-trae-related-discontinuations

Median radiographic progression free survival ("rPFS") was 9.1 months and the six-month rPFS rate was 67%No patients di...

 reported-saturday-celcuity-announces-phase-3-viktoria-1-data-gedatolisib-triplet-reduces-risk-of-progression-or-death-by-76-in-hrher2--pik3ca-wild-type-advanced-breast-cancer

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of...

 needham-reiterates-buy-on-celcuity-maintains-70-price-target

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

 celcuity-to-present-phase-3-viktoria-1-breast-cancer-data-in-late-breaking-oral-session-at-esmo-2025

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

 guggenheim-initiates-coverage-on-celcuity-with-buy-rating-announces-price-target-of-110

Guggenheim analyst Brad Canino initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of ...

 celcuitys-nda-for-gedatolisib-in-hrher2--breast-cancer-accepted-into-fdas-real-time-oncology-review-program

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

 hc-wainwright--co-maintains-buy-on-celcuity-raises-price-target-to-66

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

 needham-maintains-buy-on-celcuity-lowers-price-target-to-70

Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $74 to $70.

 celcuity-q2-adj-eps-093-misses-088-estimate

Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.88) by...

 leerink-partners-maintains-outperform-on-celcuity-raises-price-target-to-60

Leerink Partners analyst Andrew Berens maintains Celcuity (NASDAQ:CELC) with a Outperform and raises the price target from $...

 hc-wainwright--co-maintains-buy-on-celcuity-raises-price-target-to-50

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION